Last updated: March 2026
The two most popular healing peptides, head to head. BPC-157 excels at gut and tendon repair. TB-500 targets systemic tissue recovery. Different mechanisms, complementary targets — and frequently stacked together.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Full Name | Body Protection Compound-157 | Thymosin Beta-4 Fragment |
| Origin | Gastric pentadecapeptide (15 amino acids) | Active fragment of thymosin beta-4 (43 amino acids) |
| Source | Derived from human gastric juice protein | Derived from thymus gland protein |
| Primary Target | Gut, tendons, ligaments, localized repair | Muscle, cardiac, systemic tissue repair |
| Mechanism | Angiogenesis, GH receptor upregulation, NO pathway | Actin regulation, cell migration, anti-inflammation |
| Dosing | 250–500 mcg, 1–2x/day | 2–5 mg, 2x/week |
| Route | SubQ, IM, or Oral | SubQ or IM |
| Oral Stability | Yes — stable in stomach acid | No — must be injected |
| Side Effects | Very mild (rare nausea, dizziness) | Very mild (headache, lethargy) |
| FDA Status | Not approved — FDA Category 2 bulk substance (2024) | Not approved — unregulated research peptide |
| Research Level | Mostly animal studies, limited human data | Mostly animal studies, limited human data |
| Common Stack | Often combined with TB-500 | Often combined with BPC-157 |
BPC-157 and TB-500 promote healing through entirely different molecular mechanisms. This is precisely why they're so commonly stacked — they attack tissue damage from complementary angles.
A 15-amino-acid peptide derived from a protein found in human gastric juice (BPC). Promotes healing primarily through angiogenesis (new blood vessel formation), upregulation of growth hormone receptors, activation of the nitric oxide (NO) pathway, and modulation of the FAK-paxillin signaling cascade. Shows remarkable stability in stomach acid — one of the few peptides with genuine oral bioavailability.
The active fragment of thymosin beta-4 (Tβ4), a 43-amino-acid protein naturally produced in the thymus and found in most human cells. Works primarily through actin sequestration and regulation — controlling cytoskeleton dynamics that enable cell migration, proliferation, and differentiation. Also downregulates inflammatory cytokines and promotes stem cell maturation for systemic tissue repair.
Based on published preclinical research. Ratings reflect relative strength of evidence and reported efficacy in animal models. Neither compound has completed large-scale human clinical trials for these indications.
BPC-157 and TB-500 are among the most commonly stacked peptides in the research community. The rationale is mechanistic — they attack tissue damage through entirely different pathways.
BPC-157 builds new blood vessels (angiogenesis) to supply the damaged area while upregulating growth factor receptors. TB-500 mobilizes cells to the injury site by regulating cytoskeleton dynamics (actin) and reducing inflammatory signaling. Together, they theoretically address both the "supply line" (blood flow) and the "repair crew" (cell migration) simultaneously.
Dosing protocols come from published research and community protocols — not FDA-approved guidelines. These are research-context dosages only. Always consult a physician.
Both BPC-157 and TB-500 show very mild side effect profiles in published research. Most reported effects are minor and transient. However, long-term safety data in humans is extremely limited for both compounds.
Important context: "Mild side effects" doesn't mean "proven safe." Both peptides lack Phase 1/2/3 human clinical trials. The side effect data comes primarily from animal studies and community self-reports. Long-term effects, rare adverse events, and drug interactions are essentially unknown. Absence of evidence is not evidence of absence.
Neither peptide is FDA-approved. Both are sold as "research chemicals" — not for human consumption. The regulatory landscape has been shifting, particularly for BPC-157.
FDA crackdown on BPC-157: In late 2023/2024, the FDA moved BPC-157 to Category 2 of its bulk drug substances list, effectively blocking compounding pharmacies from producing it for patients. This was a significant access change — previously many users obtained BPC-157 through compounding pharmacies with a doctor's prescription. Research peptide vendors remain the primary source, but these products are not regulated for human use and purity varies by vendor.
Based on published research targets. This is not medical advice — neither compound is approved for human therapeutic use. Many researchers use both simultaneously.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. It is not medical advice. Neither BPC-157 nor TB-500 is FDA-approved for human use. Both are sold as research chemicals only. BPC-157 was placed on the FDA's Category 2 bulk drug substances list in 2024, effectively blocking compounding pharmacy production. TB-500 is banned by WADA and most sporting organizations. Most published research is preclinical (animal studies) — large-scale human clinical trials have not been conducted for either compound. Dosing information reflects research protocols, not medical recommendations. Research peptide purity and identity are not guaranteed by vendors. Always consult a qualified healthcare provider. MeetPeptide does not sell peptides or endorse their use outside of legitimate research settings.